Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

Staff Writer
Staff Writer 1 year ago
Updated 2022/05/18 at 1:17 AM
Share
SHARE

A new study by two experts at Northwestern University has shown that an experimental drug known as NU-9 can be more effective for treating amyotrophic lateral sclerosis (ALS) than existing FDA-approved drugs.

As emphasized in the latest findings in Scientific Reports, the experimental drug NU-9 lengthened the axons of diseased neurons in the rodent subjects tested.

“Here, we describe a novel in vitro platform that takes advantage of an upper motor neurons (UMNs) reporter line in which UMNs are genetically labeled with fluorescence and have misfolded SOD1 toxicity,” according to the study’s authors.

“We report that NU-9, an analog of the cyclohexane-1,3-dione family of compounds, improves the health of UMNs with misfolded SOD1 toxicity more effectively than riluzole or edaravone, -the only two FDA-approved ALS drugs to date-.”

The findings suggest that the drug’s efficacy revolves around its ability to improve axon outgrowth and axon health.

“This is very important for connecting the brain and the spinal cord and for revitalizing the motor neuron circuitry that degenerates in patients,” said the study’s lead author in a news release.

Photo: Freepik

You Might Also Like

Study boasts MDMA-assisted therapy for PTSD patients

How the brain is organized is revealed by the largest genetic study of brain structure to date

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

New study reveals positive results from postpartum depression treatment Zuranolone

New study explores magic mushrooms for anorexia nervosa psychopathology

TAGGED: axon health, NU-9, ALS
Staff Writer May 17, 2022
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article How adolescent binge drinking can significantly affect brain function
Next Article New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

Recommended

Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
Clinical

How the brain is organized is revealed by the largest genetic study of brain structure to date

2 Min Read
Clinical

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

3 Min Read
Clinical

New study reveals positive results from postpartum depression treatment Zuranolone

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?